Efficacy and safety of local application of Vijaya oil in the management of Sandhivata with special reference to Osteoarthrosis: An open-labeled single-arm clinical trial

Shehla Akhlak; Godatwar Pawankumar; Gavali Preeti; Sharma Reetu; Patel Neeraj; Peston Jahan James; Dhuri Kalpana

doi:10.21760/jaims.8.2.1

Shehla Akhlak Post Graduate Scholar, Dept. of Rog Nidana evam Vikirti Vigyan, National Institute of Ayurveda Deemed to be University, Jaipur, Rajasthan, India.
Godatwar Pawankumar Professor and HOD, Dept. of Rog Nidana evam Vikirti Vigyan, National Institute of Ayurveda Deemed to be University, Jaipur, Rajasthan, India.
Gavali Preeti Assistant Professor, Dept. of Rog Nidana evam Vikirti Vigyan, National Institute of Ayurveda Deemed to be University, Jaipur, Rajasthan, India.
Sharma Reetu Associate Professor, Dept. of Rog Nidana evam Vikirti Vigyan, National Institute of Ayurveda Deemed to be University, Jaipur, Rajasthan, India.
Patel Neeraj Head of Research and Development, Bombay Hemp Company, Mumbai, Maharashtra, India.
Peston Jahan James Chief Strategy Officer, Bombay Hemp Company, Mumbai, Maharashtra, India.
Dhuri Kalpana Professor and HOD, Dept. of Kaumarbhritya, DY Patil School of Ayurveda, Mumbai, Maharashtra, India.

DOI: https://doi.org/10.21760/jaims.8.2.1

Keywords: Sandhivata, osteoarthrosis, WOMAC, VAS (visual analog scale), GAS, ODS.

Abstract

Background: Osteoarthrosis is the second most common rheumatologic problem in India. Symptoms of Osteoarthrosis resemble Sandhivata in Ayurveda. Vijaya (cannabis sativa) oil manufactured by Bombay Hemp Company is used as a topical application in patients suffering from Sandhivata. Aim: To evaluate the efficacy & safety of local application of Vijaya oil in patients suffering from Sandhivata, with special reference to Osteoarthrosis. Materials and methods: Present clinical study was an open-label, single-arm study for the management of Sandhivata aged 30-75. The oil was applied locally on the affected site for 2 months. A total of 42 eligible patients suffering from symptomatic OA were enrolled, and 40 completed the study. Patients were assessed by clinical sign and symptom score for Sandhivata, Visual Analog Scale for Pain (VAS), WOMAC score for pain, stiffness, and physical function difficulty, Quality of life (QOL) score, Global assessment scale (GAS), and Overall disease severity (ODS). Statistical analysis was done by the Wilcoxon test. Results: The result was highly significant for all the subjective parameters. Conclusion: The study revealed that Vijaya oil significantly reduced pain, and stiffness, improved quality of life, and physical functions. It could be concluded that Vijaya oil can be a used as safe and effective drug of choice in patients suffering from Sandhivata.

Downloads

Download data is not yet available.

References

Mahajan A, Jasrotia DS, Manhas AS, Jamwal SS. Prevalence of major rheumatic disorders in Jammu. JK Science 2003; 5: 63-66.

Bhatt S, Gupta V, Srikanth N. WHO India Country Office Collaborative Study: Technical Report. New Delhi: CCRAS, Dept. of AYUSH, Ministry of H and FW, Govt. of India; 2007. [Last accessed on 2011 Aug 5]. Feasibility of Integrating Ayurveda with Modern System of Medicine in a Tertiary Care Hospital for Management of Osteoarthritis (Knee): An Operational Study. Available from: http://www.ccras.nic

www.veterans.gc.ca

Tanchev P, Osteoarthrosisorosteoarthrosis commentary on misuse of terms, JISRF Reconstructive Review, vol 7 no 1 , March 2017 , page 46-47

Maudens P, Jordan O, Allémann E. Recent advances in intra-articular drug delivery systems for osteoarthritis therapy. Drug Discov Today. 2018;23:1761–1775.

Agnivesha, Charaka Samhita, with commentary Chakrapanidatta, Edited by Vaidya Jadavaji Trikamji Acharya Chaukhabha Sanskrita Sansthan, Varanasi, Chikitsasthan, Vātavyadhichikitsa Adhyaya: chapter 28/37, p617-620.

Agnivesha, Charaka Samhita, with commentary Chakrapanidatta, Edited by Vaidya Jadavaji Trikamji Acharya. Chaukhabha Sanskrita Sansthan, Varanasi, 2011 (1stEd). Sutrastan; Snehadhyaya : chapter 13/44, p84.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, et al. Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther. 2005;27:1196–1214.

National Center for Complementary and Alternative Medicine. 2010. NCCAM Backgrounder: Massage Therapy: An Introduction.

Brown MB, Martin GP, Jones SA, et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006;13:175-87

Stanos SP. Osteoarthritis guidelines: a progressive role for topical nonsteroidal anti-inflammatory drugs. J MultidiscipHealthc 2013;6:133-7.

Tavhare Swagata et al. Exploring the pharmaco-clinical view on bhanga (cannabis sativa linn.): a classical unfamiliar portrayal, IJPBA, Nov-Dec, 2017, 8(6): 59-78.

Hammell D.C., Zhang L.P., Ma F., Abshire S.M., McIlwrath S.L., Stinchcomb A.L., Westlund K.N. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur. J. Pain. 2016;20:936–948. doi: 1002/ejp.818.

Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 2000;97:9561–9566. doi: 10.1073/pnas.160105897.

Bhavmishra, Bhavprakash Nighantu, edition 1998: verse 233, page no- 141-145.

Pandey G.S, Chunekar K C, editors. Bhavaprakasha Nighantu of Shri Bhavamishra. Haritakyadi Varga, Ver. 233.234. Revised edition. Varanasi: Chaukhambha Bharati Academy; 2010. p. 136.

Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46:207.